This Morning's Technical Outlook on Biotech Stocks -- DelMar Pharma, Galena Biopharma, Heat Biologics, and Idera Pharma

Friday, December 1, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 1, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,

WallStEquities.com has issued free tailored Stock Review on DMPI, GALE, HTBX, and IDRA which is a click away at www.wallstequities.com/registration. This morning's focus is shifted on the Biotechnology, which is a highly volatile and unpredictable
sector due to the scientifically intensive operations of companies that reside in it. Stock prices in this space can fluctuate dramatically, particularly in response to news developments concerning the success or failure of a particular drug. Today, WallStEquities.com monitors the performance of the following companies: DelMar Pharmaceuticals Inc. (NASDAQ: DMPI), Galena Biopharma Inc. (NASDAQ: GALE), Heat Biologics Inc. (NASDAQ: HTBX), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). With Wall St. Equities' free research reports get an edge over stock markets, sign up now at: www.wallstequities.com/registration

DelMar Pharmaceuticals

Vancouver, Canada headquartered DelMar Pharmaceuticals Inc.'s shares dropped 2.41%, closing Thursday's trading session at $0.94. The stock recorded a trading volume of 477,506 shares. The Company's shares have advanced 6.73% in the last month. The stock is trading 6.67% above its 50-day moving average. Additionally, shares of DelMar Pharma, which focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy, have a Relative Strength Index (RSI) of 57.10. 

On November 13th, 2017, DelMar Pharma announced its financial results for Q1 FY18. Net loss for the quarter was $2,666,406; R&D expenses increased to $1,939,617; and G&A expenses decreased to $676,258. At September 30th, 2017, the Company had cash and clinical trial deposits on hand of approximately $14.1 million. Our free and thorough report on DMPI awaits you at: www.wallstequities.com/registration/?symbol=DMPI

Galena Biopharma

On Thursday, shares in San Ramon, California-based Galena Biopharma Inc. recorded a trading volume of 279,193 shares. The stock declined 0.35%, ending the day at $0.31. The Company's shares are trading below their 50-day moving average by 9.82%. Furthermore, shares of Galena Biopharma, which develops hematology and oncology therapeutics that address unmet medical needs, have an RSI of 47.92. 

On November 09th, 2017, Galena Biopharma reported its financial results for the quarter ended September 30th, 2017. Operating loss for Q3 2017 was $4.5 million, loss from continuing operations was $6.2 million, income from discontinued operations was $0.1 million, and net loss was $6.1 million. As of September 30th, 2017, the Company had cash and cash equivalents of approximately $12.9 million. GALE's complimentary research coverage is a few simple steps away at: www.wallstequities.com/registration/?symbol=GALE

Heat Biologics

Durham, North Carolina-based Heat Biologics Inc.'s stock finished the day 4.66% lower at $0.46 with a total trading volume of 242,588 shares. The stock is trading below their 50-day moving average by 23.36%. Shares of the Company, which focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the US, have an RSI of 35.61. 

On November 13th, 2017, Heat Biologics reported its results for Q3 ended September 30th, 2017. R&D expenses for Q3 2017 increased to approximately $1.8 million; G&A expenses increased to $1.2 million; and net loss was $2.3 million. Cash and cash equivalents totaled approximately $4.3 million, as of September 30th, 2017. Register for your free research report on HTBX at: www.wallstequities.com/registration/?symbol=HTBX

Idera Pharmaceuticals

Shares in Cambridge, Massachusetts-based Idera Pharmaceuticals Inc. ended yesterday's session 1.38% higher at $2.21. The stock recorded a trading volume of 1.51 million shares. The Company's shares have advanced 41.67% in the last one month, 11.62% over the previous three months, and 47.33% since the start of this year. The stock is trading 2.49% and 11.33% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Idera Pharma, which focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the US, have an RSI of 56.00. 

On November 09th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $4 per share.

On November 29th, 2017, Idera Pharma announced that the US FDA has granted Fast Track designation for the Company's lead development candidate IMO-2125 in combination with Ipilimumab for the treatment of anti-PD-1 refractory metastatic melanoma in combination with ipilimumab therapy. FDA's Fast Track program is designed to expedite the development and review of drugs and biologics to treat serious or life-threatening conditions with non-clinical or clinical data, demonstrating the potential to address unmet medical needs. Wall St. Equities' downloadable research report on IDRA available at: www.wallstequities.com/registration/?symbol=IDRA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit  https://wallstequities.com/legal-disclaimer/

CONTACTFor any questions, inquiries, or comments reach out to us directly.If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-biotech-stocks----delmar-pharma-galena-biopharma-heat-biologics-and-idera-pharma-300565003.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store